Vigil Neuroscience (NASDAQ:VIGL) Given New $14.00 Price Target at HC Wainwright

Vigil Neuroscience (NASDAQ:VIGL) had its price objective decreased by investment analysts at HC Wainwright from $17.00 to $14.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock.

A number of other brokerages have also weighed in on VIGL. Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. JMP Securities reaffirmed a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Finally, William Blair began coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $19.00.

Vigil Neuroscience Stock Performance

Shares of NASDAQ VIGL opened at $2.11 on Friday. Vigil Neuroscience has a fifty-two week low of $1.49 and a fifty-two week high of $6.06. The company has a market cap of $86.25 million, a price-to-earnings ratio of -1.02 and a beta of 1.82. The business’s 50 day moving average price is $2.34 and its 200-day moving average price is $2.80.

Vigil Neuroscience (NASDAQ:VIGL) last released its earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). Sell-side analysts predict that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Institutional Investors Weigh In On Vigil Neuroscience

Several large investors have recently modified their holdings of VIGL. abrdn plc boosted its stake in shares of Vigil Neuroscience by 124.9% during the fourth quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after purchasing an additional 293,461 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Vigil Neuroscience by 41.9% in the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after acquiring an additional 66,712 shares during the period. Verition Fund Management LLC purchased a new position in shares of Vigil Neuroscience in the 3rd quarter valued at $442,000. Walleye Capital LLC raised its position in shares of Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after acquiring an additional 92,217 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Vigil Neuroscience by 7.7% during the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock valued at $5,440,000 after purchasing an additional 115,000 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.